Stevens Capital Management LP Exelixis, Inc. Transaction History

Stevens Capital Management LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 06, 2020	SELL	$15.15 - $18.89 $477,406 - $595,261	-31,512 Closed	0 $0
Q3 2019 Nov 08, 2019	SELL	$17.68 - $22.65 $1.3 Million - $1.67 Million	-73,585 Reduced 70.02%	31,512 $557,000
Q2 2019 Jul 31, 2019	BUY	$18.93 - $24.75 $36,345 - $47,520	1,920 Added 1.86%	105,097 $2.25 Million
Q1 2019 May 03, 2019	BUY	$19.6 - $24.76 $2.02 Million - $2.55 Million	103,177 New	103,177 $2.46 Million
Q4 2018 Feb 06, 2019	SELL	$13.65 - $21.8 $1.64 Million - $2.61 Million	-119,945 Closed	0 $0
Q3 2018 Nov 13, 2018	BUY	$15.87 - $22.4 $715,768 - $1.01 Million	45,102 Added 60.26%	119,945 $2.13 Million
Q2 2018 Aug 09, 2018	BUY	$18.56 - $22.45 $1.18 Million - $1.42 Million	63,335 Added 550.36%	74,843 $1.61 Million
Q1 2018 May 08, 2018	BUY	$22.15 - $31.89 $254,902 - $366,990	11,508 New	11,508 $255,000
Q4 2017 Feb 13, 2018	SELL	$24.23 - $30.93 $3.08 Million - $3.93 Million	-127,049 Closed	0 $0
Q3 2017 Nov 01, 2017	BUY	$23.35 - $29.24 $2.97 Million - $3.71 Million	127,049	127,049 $3.08 Million

502

243M

2.54M

2.29M

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $10.9B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

Get notified when there are updates to the investment portfolio of Stevens Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Stevens Capital Management LP with notifications on news.